Cellartis
Cellartis AB is a Swedish/British biotechnology company focused on human embryonic stem (hES) cells for drug discovery, toxicity testing and regenerative medicine with the main objective to develop hepatocytes and cardiomyocytes from these cells.
Key products |
|
|
|
|
CARDIOMYOCYTES |
![]() |
HEPATOCYTES |
![]() |
PLATFORM AND ASSAY DEVELOPMENT |
Latest News
Cellartis and ReproCELL Sign Agreement to Provide CardioToxicity screening service using hESC derived Cardiomyocytes
read more
AstraZeneca and Cellartis extend their collaboration to develop new way to test drug safety using stem cells
read more
Cellartis signs licence deal with ITI life Sciences to commercialise large scale hES cell production
read more
Calendar
Translational Regenerative Medicine – scaling up from lab to clinic, Cellartis invited speaker, London, UK
Cell-Based Assays Conference, London, UK
World Stem Cells & Regenerative Medicine Congress, Cellartis invited speaker, London, UK





